Cutler Group LP Editas Medicine, Inc. Call Options Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Jan 18, 2022	SELL	$26.55 - $40.57 $1.45 Million - $2.22 Million	-54,700 Reduced 98.03%	1,100 $0
Q3 2021 Oct 26, 2021	BUY	$39.27 - $72.94 $1.95 Million - $3.63 Million	49,700 Added 814.75%	55,800 $3,000
Q2 2021 Jul 19, 2021	BUY	$31.29 - $56.64 $96,999 - $175,584	3,100 Added 103.33%	6,100 $33,000
Q1 2021 Apr 26, 2021	BUY	$39.71 - $90.58 $11,913 - $27,174	300 Added 11.11%	3,000 $0
Q4 2020 Jan 21, 2021	SELL	$27.07 - $84.35 $194,904 - $607,320	-7,200 Reduced 72.73%	2,700 $81,000
Q3 2020 Oct 27, 2020	BUY	$28.06 - $37.16 $109,434 - $144,924	3,900 Added 65.0%	9,900 $14,000
Q4 2019 Feb 06, 2020	BUY	$19.49 - $32.63 $97,449 - $163,150	5,000 Added 500.0%	6,000 $2,000
Q1 2019 May 10, 2019	SELL	$19.43 - $26.41 $170,984 - $232,408	-8,800 Reduced 89.8%	1,000 $2,000
Q2 2018 Aug 10, 2018	SELL	$31.4 - $41.01 $210,380 - $274,767	-6,700 Reduced 40.61%	9,800 $68,000
Q1 2018 May 11, 2018	SELL	$29.84 - $44.08 $161,136 - $238,032	-5,400 Reduced 24.66%	16,500 $89,000
Q4 2017 Jan 17, 2018	BUY	$21.89 - $31.34 $302,082 - $432,492	13,800 Added 170.37%	21,900 $104,000
Q3 2017 Oct 17, 2017	BUY	$15.81 - $24.01 $128,061 - $194,481	8,100	8,100 $23,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.